文献速递MDS 与骨髓增殖性肿瘤

克拉屈滨治疗晚期与惰性系统性肥大细胞增多症:Mayo Clinic 42例连续病例经验

Cladribine therapy for advanced and indolent systemic mastocytosis: Mayo Clinic experience in 42 consecutive cases.
PubMed 文献 · Br J Haematol · 2021-11-03

本文报告单中心42例系统性肥大细胞增多症(SM)患者接受克拉屈滨治疗的经验,其中晚期SM 22例、惰性/冒烟型SM 20例。晚期SM总缓解率77%、主要缓解率45%,惰性/冒烟型SM分别为70%和60%。晚期SM中KITD816V突变预测缓解,未突变者均未缓解,该发现需更大样本研究确认。

要点

  • 晚期SM总缓解率77%、主要缓解率45%,中位缓解持续时间10个月(范围4-75个月)。
  • 惰性/冒烟型SM总缓解率70%、主要缓解率60%,中位缓解持续时间46个月(范围4-140个月)。
  • 晚期SM中KITD816V突变者19例中17例(90%)缓解,无突变者3例均未缓解(P<0.01)。

核心结论

  • 克拉屈滨对晚期SM和惰性/冒烟型SM均有治疗活性,晚期SM中KITD816V缺失可能是克拉屈滨耐药的潜在标志,但需更大样本研究确认。

研究设计与样本

  • 单中心连续病例经验,纳入42例系统性肥大细胞增多症患者,其中晚期SM 22例(中位年龄65岁,男性68%),惰性/冒烟型SM 20例(中位年龄56岁,男性45%)。
  • 亚型包括侵袭性SM 8例、伴其他血液肿瘤SM 13例、肥大细胞白血病1例、惰性SM 17例、冒烟型SM 3例。

主要发现

  • 晚期SM总缓解率77%、主要缓解率45%,中位缓解持续时间10个月(范围4-75个月);惰性/冒烟型SM总缓解率70%、主要缓解率60%,中位缓解持续时间46个月(范围4-140个月)。
  • 骨髓肥大细胞负荷下降>50%者在晚期SM为63%、惰性/冒烟型SM为50%;血清类胰蛋白酶水平下降>50%者在晚期SM为67%、惰性/冒烟型SM为46%。
  • 晚期SM中KITD816V突变者19例中17例(90%)缓解,无突变者3例均未缓解(P<0.01)。
  • 治疗中出现的不良事件主要限于一过性血细胞减少:晚期SM中3/4级中性粒细胞减少、血小板减少、淋巴细胞减少分别占27%、27%、27%,惰性/冒烟型SM分别占5%、5%、30%。

临床怎么用

  • 本研究提供的信息可能有助于在克拉屈滨与新型KIT靶向治疗之间做出治疗选择。
  • 晚期SM中KITD816V缺失被识别为克拉屈滨耐药的潜在标志。

局限性

  • 原文指出KITD816V缺失作为克拉屈滨耐药标志的观察需在更大样本研究中确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We describe our single institution experience with cladribine therapy in 42 patients with systemic mastocytosis (SM): 22 advanced (adv-SM; median age 65 years, 68% males) and 20 indolent/smouldering SM (ISM/SSM; median age 56 years, 45% males); subcategories included eight aggressive, 13 associated with another haematological neoplasm, one mast cell leukaemia, 17 ISM and three SSM. Overall/major response rates were 77%/45% for adv-SM and 70%/60% for ISM/SSM, and median (range) duration of response 10 (4-75) and 46 (4-140) months respectively. A >50% reduction in bone marrow mast cell burden and serum tryptase level was documented in 63% and 67% of patients with adv-SM and 50% and 46% with ISM/SSM respectively. The presence of KIT proto-oncogene, receptor tyrosine kinase (KIT)D816V predicted response in adv-SM: 17 (90%) of 19 with and none of three without the mutation responded (P < 0·01). Treatment-emergent adverse events were mostly limited to transient cytopenias: Grade 3/4 neutropenia, thrombocytopenia, or lymphopenia occurred in 27%, 27% and 27% of patients with adv-SM, and 5%, 5% and 30% with ISM/SSM respectively. The present study provides practical information that might be considered when making treatment choices between cladribine and newer KIT-targeted therapies and identifies the absence of KITD816V as a potential marker of cladribine resistance in advanced SM; the latter observation needs confirmation in a larger study.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Tefferi A, Kittur J, Farrukh F, et al. Cladribine therapy for advanced and indolent systemic mastocytosis: Mayo Clinic experience in 42 consecutive cases. Br J Haematol. 2021. PMID: 34729775. doi:10.1111/bjh.17932

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。